Understanding the MDR1 Mutation in Australian Shepherd

The MDR1 gene, also known as the Multidrug Resistance 1 gene or ABCB1, plays a crucial role in how dogs process certain medications. In its normal form, this gene codes for a protein called P-glycoprotein, which acts like a pump to remove toxins and drugs from cells, particularly at protective barriers in the body such as the blood-brain barrier, intestines, kidneys, and placenta. This protein helps prevent harmful substances from accumulating in sensitive areas like the brain. However, a specific mutation in the MDR1 gene—a deletion of four base pairs—results in a defective or non-functional P-glycoprotein. Dogs carrying this mutation cannot effectively clear certain drugs from their systems, leading to toxic buildup, especially in the brain, which can cause severe neurological symptoms. This mutation is inherited in an autosomal recessive manner, meaning a dog can have zero, one, or two copies of the mutated gene. Dogs with two copies (mutant/mutant or homozygous) are at the highest risk and have essentially no functional P-glycoprotein, making them extremely sensitive to affected drugs. Even dogs with one copy (normal/mutant or heterozygous) can experience adverse effects, though they may be milder or require higher doses to trigger a reaction. The severity of reactions depends on factors like the drug’s dosage, the dog’s genotype, and individual variability.

How MDR1 Affects Australian Shepherds

Australian Shepherds are one of the breeds most commonly affected by the MDR1 mutation, with approximately 50% of the population carrying at least one copy of the gene. This high prevalence is similar in Miniature Australian Shepherds (also around 50%) and is thought to stem from the breed’s herding dog ancestry, shared with breeds like Collies (70% prevalence). In Aussies, the mutation can lead to life-threatening reactions when exposed to certain medications, as the defective P-glycoprotein allows drugs to cross the blood-brain barrier and accumulate, causing neurological toxicity.

Symptoms of a reaction can include excessive salivation, ataxia (loss of coordination), tremors, seizures, coma, and even death. For example, a common scenario involves heartworm preventives or antiparasitic treatments; while low doses might be tolerated in some mutant dogs, higher doses (e.g., for treating mange) can be fatal. Other drugs might cause subtler issues, like prolonged sedation from anesthetics or gastrointestinal toxicity from chemotherapy agents.

"The Waggoner" - Brushy Creek's Heritage Collection Hand Tooled Collar

Buy Now

The impact on Australian Shepherds is particularly significant because these active, working dogs are often exposed to veterinary care for parasites, injuries, or routine procedures. Without awareness of their MDR1 status, a routine treatment could turn deadly. 

Problematic Drugs and Brand Names

Not all drugs are affected by the MDR1 mutation—only those that rely on P-glycoprotein for clearance.  Below is a list of commonly problematic drugs, including active ingredients, brand names (where applicable), and recommendations based on veterinary guidelines. This is not exhaustive, and you should always consult a veterinarian familiar with MDR1 for personalized advice. Some drugs are safe at low doses but dangerous at higher ones, while others should be avoided entirely.

• Ivermectin (e.g., Heartgard Plus, Ivomec): Commonly used for heartworm prevention and parasite treatment. Safe at low heartworm doses for mutant dogs (per FDA), but avoid high doses (e.g., for mange or worming) as they can cause severe neurological toxicity.  

• Loperamide (e.g., Imodium): An over-the-counter antidiarrheal. Avoid entirely in mutant dogs, as even standard doses can lead to neurological issues.   

• Milbemycin (e.g., Interceptor, Interceptor Plus): Heartworm preventive. Safe at label doses for mutant dogs (per FDA), but consult for other formulations.  

• Moxidectin (e.g., ProHeart, Simparica Trio, NexGard Plus, Advantage Multi): Antiparasitic. Safe at label doses for mutant dogs. 

• Selamectin (e.g., Revolution): Topical parasite control. Safe at label doses.  

• Acepromazine: Sedative/anesthetic. Can cause prolonged or excessive sedation; dose adjustments needed.   

• Butorphanol (e.g., Torbugesic): Pain reliever/sedative. Similar to acepromazine; consult for dosing.  

• Chemotherapy drugs (e.g., Doxorubicin, Vincristine, Vinblastine, Vinorelbine): Used in cancer treatment. Can cause severe gastrointestinal toxicity and bone marrow suppression even at low doses; dose reductions (often 25-30%) or alternatives recommended.   

• Cyclosporine (e.g., Atopica): Immunosuppressant for skin conditions. Consult for dosing. 

• Apomorphine: Emesis inducer. Consult for dosing. 

• Maropitant (e.g., Cerenia): Antiemetic. Consult for dosing. 

• Ondansetron: Antiemetic. Consult for dosing. 

• Grapiprant (e.g., Galliprant): Pain reliever for arthritis. Consult for dosing. 

Note that some flea/tick products like Afoxolaner (NexGard), Fluralaner (Bravecto), and Sarolaner (Simparica) have been tested and are safe for MDR1 mutant dogs.  Always check product labels and consult resources like MDR1Caddie™ for the latest recommendations. 

Why Testing Your Australian Shepherd or Buying from a Reputable Breeder is Crucial

Testing for the MDR1 mutation is a simple, one-time DNA test (via cheek swab or blood sample) that determines your dog’s genotype: Normal/Normal (clear, no risk), Normal/Mutant (carrier, at risk), or Mutant/Mutant (affected, highest risk).   It’s essential for all Australian Shepherds, as knowing the status allows you to inform your veterinarian, who can choose safer alternatives or adjust doses to prevent adverse reactions.   For instance, if your dog needs surgery or parasite treatment, this knowledge can save their life. Reactions are preventable but can be fatal if ignored—many owners only discover the mutation after a crisis.  Testing is recommended even for rescues or mixed breeds with herding ancestry, and results should be shared with anyone caring for the dog (e.g., via a medic alert tag). 

When acquiring an Australian Shepherd, prioritize reputable breeders who test their breeding stock for MDR1 (along with other health issues like hips and eyes).  Ethical breeders will provide proof of parents’ test results and only breed mutant dogs to clear ones to produce healthier litters, gradually reducing the mutation’s frequency in the breed without narrowing the gene pool.  Avoid breeders who don’t test, as this increases the chance of getting a puppy at risk. Puppies from two clear parents don’t need testing, but if one parent is a carrier, test the litter.  By choosing tested lines, you’re investing in a healthier dog and supporting efforts to improve the breed overall.

In summary, the MDR1 mutation is a manageable but serious genetic issue in Australian Shepherds. With testing and informed care, affected dogs can live full, healthy lives—but ignorance can lead to tragedy.